These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1265484)

  • 1. Phytohemagglutinin-induced lymphocyte transformation in humans receiving delta9-tetrahydrocannabinol.
    Lau RJ; Tubergen DG; Barr M; Domino EF; Benowitz N; Jones RT
    Science; 1976 May; 192(4241):805-7. PubMed ID: 1265484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marihuana, tetrahydrocannabinol and T-cell function.
    Petersen BH; Graham J; Lemberger L
    Life Sci; 1976 Aug; 19(3):395-400. PubMed ID: 1085394
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of delta9-tetrahydrocannabinol and cannabinol in man.
    Karniol IG; Shirakawa I; Takahashi RN; Knobel E; Musty RE
    Pharmacology; 1975; 13(6):502-12. PubMed ID: 1221432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensory, perceptual, motor and cognitive functioning and subjective reports following oral administration of delta9-tetrahydrocannabinol.
    Peters BA; Lewis EG; Dustman RE; Straight RC; Beck EC
    Psychopharmacologia; 1976 May; 47(2):141-8. PubMed ID: 1273209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.
    ElSohly MA; deWit H; Wachtel SR; Feng S; Murphy TP
    J Anal Toxicol; 2001 Oct; 25(7):565-71. PubMed ID: 11599601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Induction of lymphoblastic transformation with delta-9-tetrahydrocannabinol in mice].
    Nagel MD; Zagury D; Nahas G
    C R Acad Hebd Seances Acad Sci D; 1973 Feb; 276(6):1089-91. PubMed ID: 4196778
    [No Abstract]   [Full Text] [Related]  

  • 7. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid.
    Manno JE; Manno BR; Kemp PM; Alford DD; Abukhalaf IK; McWilliams ME; Hagaman FN; Fitzgerald MJ
    J Anal Toxicol; 2001 Oct; 25(7):538-49. PubMed ID: 11599597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerance to the cardiovascular effects of delta9-tetrahydrocannabinol in the rat.
    Adams MD; Chait LD; Earnhardt JT
    Br J Pharmacol; 1976 Jan; 56(1):43-8. PubMed ID: 1252665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
    Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes.
    Brenneisen R; Meyer P; Chtioui H; Saugy M; Kamber M
    Anal Bioanal Chem; 2010 Apr; 396(7):2493-502. PubMed ID: 20112012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of chronic administration of delta9-tetrahydrocannabinol on the heart rate of mongrel dogs.
    Jandhyala BS; Malloy KP; Buckley JP
    Res Commun Chem Pathol Pharmacol; 1976 May; 14(1):201-4. PubMed ID: 935652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogen-induced blastogenic responses of lymphocytes from marihuana smokers.
    White SC; Brin SC; Janicki BW
    Science; 1975 Apr; 188(4183):71-2. PubMed ID: 1078732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of cannabinol during oral surgery.
    Gregg JM; Campbell RL; Levin KJ; Ghia J; Elliott RA
    Anesth Analg; 1976; 55(2):203-13. PubMed ID: 769605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction of delta9-tetrahydrocannabinol with cholinomimetic drugs in an agonist-antagonist paradigm.
    Jones BC; Consroe PF; Laird HE
    Eur J Pharmacol; 1976 Aug; 38(2):253-9. PubMed ID: 954840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure.
    Hart CL; Haney M; Vosburg SK; Comer SD; Foltin RW
    Psychopharmacology (Berl); 2005 Sep; 181(2):237-43. PubMed ID: 15830233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of delta9-tetrahydrocannabinol on experimental hypertension in rats.
    Varma DR; Goldbaum D
    J Pharm Pharmacol; 1975 Oct; 27(10):790-1. PubMed ID: 241799
    [No Abstract]   [Full Text] [Related]  

  • 17. Depression of growth hormone and cortisol response to insulin-induced hypoglycemia after prolonged oral delta-9-tetrahydrocannabinol administration in man.
    Benowitz NL; Jones RT; Lerner CB
    J Clin Endocrinol Metab; 1976 May; 42(5):938-41. PubMed ID: 1270583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.
    Englund A; Atakan Z; Kralj A; Tunstall N; Murray R; Morrison P
    J Psychopharmacol; 2016 Feb; 30(2):140-51. PubMed ID: 26577065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion.
    Benowitz NL; Jones RT
    Clin Pharmacol Ther; 1975 Sep; 18(3):287-97. PubMed ID: 1164818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of delta9-tetrahydrocannabinol on action potentials in the mollusc Aplysia.
    Acosta-Urquidi J; Chase R
    Can J Physiol Pharmacol; 1975 Oct; 53(5):793-8. PubMed ID: 1201484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.